Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Court Date for Biogen and Elan Set for Sept. 3

This article was originally published in The Pink Sheet Daily

Executive Summary

The partners, who are litigating over Tysabri, face off earlier than expected.

You may also be interested in...

A Safety Net That May Not Be So Safe: Elan Sues Biogen Over J&J Deal

Elan's new deal with J&J over its key Alzheimer's assets runs into a brick wall: Biogen.

Painting a Rosy Picture, Beleaguered Elan Seeks To Leave Its Troubles Behind

Elan reveals a hidden sweetener in its J&J deal, which will enable it to bid for the half of Tysabri it doesn't already own in the event Biogen is bought.

J&J And Elan Strike A Deal On Key Alzheimer's Disease Assets

Six months after announcing it was looking at strategic alternatives, Elan's beleaguered management has found a way to address its challenges: It announced July 2 that it is selling its Alzheimer's immunotherapy program (AIP), which includes the high-profile Alzheimer's disease drug bapineuzumab and all related assets, to Johnson & Johnson for what essentially amounts to $500 million in the near-term and a commitment from J&J to buy an 18.4 percent stake in Elan for $1 billion

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts